Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Janssen/Shire Reminyl

Executive Summary

Alzheimer's treatment slated for early 2001 launch after receipt of "approvable" letter July 31 from FDA, Shire said. While the agency has requested additional data, Janssen said it expects to be able to use currently available data to satisfy the request. Janssen filed the NDA for galantamine on Sept. 29, 1999

You may also be interested in...



Janssen/Shire Reminyl

"Hopefully we will be receiving the final [Reminyl] approval in a reasonable time frame," J&J CEO Ralph Larsen tells Jan. 23 analysts meeting. "We are prepared and have taken steps to introduce this important product into the U.S. very rapidly." The Alzheimer's agent galantamine has been "approvable" at FDA since July 31 (1"The Pink Sheet" Aug. 7, 2000, In Brief)

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
UsernamePublicRestriction

Register

PS036472

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel